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Introduction: Acute exacerbation of chronic obstructive pulmonary disease  
 
(AECOPD) is very critical, high mortality disease1). It is very important in  
 
chronic obstructive pulmonary disease (COPD) patients, and airway  
 
infection, especially viral infection, is its major cause2). There is no definitive  
 
management to control airway inflammation induced by viral infection in  
 
COPD patients, although many clinicians have very high interests. How do  
 
we control airway inflammation and how do we prevent AECOPD?---There is  
 
nothing conclusive, but many researchers try to find a new agent that has  
 
anti-airway inflammatory effect. 
 
Respiratory syncytial virus (RSV) is known as major cause of young  
children’s airway infection, especially as cause of bronchiolitis3). Recently it  
 
is realized that this organism may be one of cause of adult bronchitis and  
 
bronchiolitis4). Therefore it is estimated that this organism is harmful for  
 
COPD patient and may be one of cause of AECOPD through airway  
 
inflammation5).  
 
There are some agents to control airway inflammation, e.g.  
 
clarithromycin6), L-carbocysteine7), and tiotropium bromide8). These agents  
 
suppress cytokines derived from airway inflammatory cells. Lysozyme  
 
hydrochloride is commonly administered in Japan as anti-inflammatory  
 agent, especially for chronic airway inflammation. However, its actual  
 
molecular potential is still unknown. To confirm whether this classical drug  
 
has anti-airway inflammatory effect, we examined the anti-RSV effect of  
 
lysozyme hydrochloride by using HEp-2 cells. 
  
Material and Methods: This study is a preclinical study. Institutional Review  
 
Board approval was not obtained, since it was not necessary for a basic  
 
study. 
 
 RSV A2 strain was obtained from ATCC (Rockville, Md., USA). RSV stocks  
 
were prepared as described previously9).  
 
 HEp-2 cells (CCL-23) were obtained from ATCC (Rockville, Md., USA), and  
 
maintained in Eagle’s Minimum Essential Media supplemented with  
 
glutamine and 10% fetal bovine serum (FBS). 
 
 Lysozyme hydrochloride were obtained from Eisai Co.,Ltd., Japan. 
 
Preliminary study: A viral titer of supernatants was unchanged 48 hours  
 
after infection with RSV at a multiplicity of infection (MOI) of 0.1, and  
 
5ng/ml lysozyme hydrochloride. 
 
 Cell viability was not changed with 5ng/ml lysozyme hydrochloride,  
 
assessed by ATP assay. 
 Measurement of cytokines: The effect of lysozyme hydrochloride on cytokine  
 
expression after RSV infection was examined with treating the cells 0, 5, 50,  
 
500 pg/ml and  
 
5ng/ml lysozyme hydrochloride for 3 days before and 48 hours after RSV  
 
infection at an MOI of 0.1. The supernatants were collected and the  
 
cytokines were measured by multiplex assay in Bio-Plex assay system  
 
(BIO-RAD Laboratories, Inc., Hercules, Ca., USA). 
 
Statistical analysis: Statistical analysis was performed with StatView  
 
software (SAS Institute, Cary, N.C., USA). All comparisons to 0pg/ml of  
 
lysozyme hydrochloride of means were made by Tukey’s test. The level of  
 
significance was set at p < 0.05. 
 
Results: The concentration of IL-6 significantly decreased at 50, 500,  
 
5000pg/ml lysozyme hydrochloride, dose dependently, compared with the  
 
control (Figure 1-a). In other way, they did not show any inhibition to  
 
product IL-8 (Figure 1-b).  IL-1β and MIP-1a were decreased by lysozyme  
 
hydrochloride, at 5,000pg/ml of lysozyme hydrochloride (Figure 1-c,d).  
 
G-CSF also decreased as to be the drug concentration (Figure 2-a), however,  
 
TNF-α increased at 5,000pg/ml of lysozyme hydrochloride (Figure 2-b), and,  
 IFN-γ did not show any significant change regardless of the drug  
 
concentration (Figure 2-c). 
 
Discussion: In the present study, we found that lysozyme hydrochloride could  
 
inhibit some of inflammatory cytokines induced by RSV infection in HEp-2  
 
cells. In other way, it was also confirmed that there were cytokines that the  
 
agent could not control, e.g. IL-8.  
 
IL-6, IL-8, IL-1β, IFN-γand TNF-α are known as important  
 
inflammatory cytokines. Our present study showed that IL-6 and IL-1β  
 
were inhibited by lysozyme hydrochloride, though IL-8, IFN-γ and TNF-α  
 
were not. The reason why there was discrepancy between them is not  
 
declarative, but three reasons were estimated. First, this agent’s competence  
 
to regulate inflammatory cytokines was partially. Second, more dosing was  
 
needed to inhibit inflammatory cytokines. Third, the target pathway of this  
 
agent was not standard one, RhoA signaling pathways. In RSV infection,  
 
RhoA signaling pathways can induce several cytokines10). If lysozyme  
 
hydrochloride may affect this pathway, both IL-6 and IL-8 can be regulated.  
 
Partial regulation in our study would make us think that this agent may  
 
affect other pathway. We need to make additional and sequential  
 experiments in vitro to confirm these points. 
 
In the present study, we showed only simple data about major inflammatory  
 
cytokines induced by RSV infection in HEp-2 cells. Data of other  
 
inflammatory cytokines, viral PCR, plaque assay, measurement cell surface  
 
ICAM-1, and RhoA activation are supposed to be needed. It is necessary to  
 
demonstrate further investigation. 
 
 We showed simple data that lysozyme hydrochloride might inhibit some of  
 
inflammatory cytokines derived from RSV infection. This simple data is not  
 
able to declare lysozyme hydrochloride can control airway infection, and  
 
further investigations are needed. 
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